BRD4-mediated repression of p53 is a target for combination therapy in AML.
Latif AL, Newcombe A, Li S, Gilroy K, Robertson NA, Lei X, Stewart HJS, Cole J, Terradas MT, Rishi L, McGarry L, McKeeve C, Reid C, Clark W, Campos J, Kirschner K, Davis A, Lopez J, Sakamaki JI, Morton JP, Ryan KM, Tait SWG, Abraham SA, Holyoake T, Higgins B, Huang X, Blyth K, Copland M, Chevassut TJT, Keeshan K, Adams PD.
Latif AL, et al. Among authors: lopez j.
Nat Commun. 2021 Jan 11;12(1):241. doi: 10.1038/s41467-020-20378-8.
Nat Commun. 2021.
PMID: 33431824
Free PMC article.